- 0.6 -2.0 USD ($)
The CareStart Covid-19 Rapid Diagnostic Antigen Test is a lateral flow immunochromatographic assay for the detection of extracted nucleocapsid protein antigens specific to SARS-CoV-2 in anterior nares swab specimens directly collected from symptomatic individuals who are suspected of COVID-19 by their healthcare provider.
As an intended point-of-care (POC) designated test performed by medical professionals with a 10 minutes processing time, CareStart Covid-19 Rapid Diagnostic Antigen Testhelps provide critical answers about active infections to patients and healthcare workers alike.
Features and Benefits
Lateral flow assay
No equipment required
Rapid results at 10 minutes
Minimally invasive specimen collection (nasopharyngeal swabs)
Detect SARS-CoV-2 nucleocapsid protein antigen with ultra high performance
Test is only authorized at this time for POC use by qualified healthcare professionals.
Test is only authorized for a diagnostic indication.
93.75% Positive Percentage Agreement (PPA) and 99.32% Negative Percent Agreement (NPA) when used with with nasopharyngeal swab
87.18% Positive Percentage Agreement (PPA) and 99.32% Negative Percent Agreement (NPA) when used with with anterior swab
Carestart COVID-19 Antigen Test
This product has not been FDA cleared or approved, but has been authorized by FDA under an EUA for use by authorized laboratories
This product has been authorized only for the detection of proteins from SARS-CoV-2, not for any other viruses or pathogens; and
- 3 Per Day
- 5-15 Days
- Asia, Australia, Central America, North America, South America, Eastern Europe, Western Europe, Middle East, Africa
- FDA EUA CE ISO GMP SFC ETC CareStart Covid-19 Rapid Diagnostic Antigen Test
28955, Avenue Sherman Valencia, California, Missouri, 91355, United States